The prognosis of HER2‐positive breast cancer has been significantly improved due to the development of HER‐2‐targeted drugs, including trastuzumab, pertuzumab, pyrotinib, and trastuzumab‐emtansine (T‐DM1). Here, ERBB2 is linked to breast carcinoma.